A novel osteotropic biomaterial OG‐PLG: Synthesis and in vitro release
Authors:
- 24 June 2005
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 74A (2) , 237-246
Abstract
Statins (e.g., simvastatin) have shown to induce expression of the bone morphogenic protein‐2 gene in bone cells, but they are not used clinically because of a lack of a suitable delivery device. The overall objective is to develop optimized statin delivery devices for bone regeneration. The specific objective was to determine the effect of grafting statins to biodegradable poly[lactide‐co‐glycolide] (PLG) on release kinetics. Simvastatin was grafted to PLG (OG‐PLG) and characterized using contact‐angle measurements, attenuated total reflectance–Fourier transform infrared, and ultraviolet–visible spectroscopy to determine success of the synthesis. An ultraviolet–visible assay for measuring release of statins and degraded OG‐PLG in media was also developed. In vitro release studies using films and scaffolds made with PLG, PLG blended with simvastatin (PLG + Sim), and OG‐PLG (simvastatin grafted to PLG) blended into PLG at different concentrations showed that release rate of OG‐PLG from films was significantly greater than that of PLG + Sim. However, release rate from scaffolds showed PLG + Sim to be significantly higher than that of OG‐PLG. The diffusion‐controlled release kinetics of simvastatin from PLG + Sim seems to be more heavily affected by device morphology, whereas the degradation‐controlled release kinetics seem to be less affected. In short, release kinetics can be modulated by grafting statins to PLG. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res, 2005Keywords
This publication has 37 references indexed in Scilit:
- Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician?Journal of Oral Science, 2003
- Simvastatin Promotes Osteoblast Differentiation and Mineralization in MC3T3-E1 CellsBiochemical and Biophysical Research Communications, 2001
- Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma CellsBiochemical and Biophysical Research Communications, 2000
- Use of Bone Morphogenetic Protein-2 in the Rabbit Ulnar Nonunion ModelClinical Orthopaedics and Related Research, 1996
- Biocompatibility of a biodegradable matrix used as a skin substitute: An in vivo evaluationJournal of Biomedical Materials Research, 1994
- Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and SimvastatinJournal of Pharmaceutical Sciences, 1991
- Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro.Journal of Cell Biology, 1991
- Physiological Cultured Skin Substitutes for Wound HealingMRS Proceedings, 1991
- Rotenoids. XX.1 Total Synthesis of RotenoneJournal of the American Chemical Society, 1965
- STEROIDS AND RELATED PRODUCTS. III. THE SYNTHESIS OF 17β-METHYL-17-ISODESOXYCORTICOSTERONECanadian Journal of Chemistry, 1955